Saturday, October 31, 2026
Data from SEC filings, checked daily
Public filings, plainly told
Summarize with AIChatGPTClaudePerplexityGoogle AIGrokCopilot
Data updated Oct 31, 2026·New filings added every weekday·Weekly prices as of Oct 2·What changed·
Insider purchase · Form 4 · Jan 12, 2026

Director Ecor1 Capital, LLC buys $40 million of Aktis Oncology, Inc. (AKTS)

Ecor1 Capital, LLC, director, bought $40 million of stock. WallStPal Score 62.

62
WallStPal ScoreHow much this purchase says, from 0 to 100. How it works

Ecor1 Capital, LLC, director of Aktis Oncology, Inc., bought 2,222,222 shares on the open market on January 12, 2026 at an average of $18.00 a share, for a total of $40 million. The purchase was reported to the SEC on Form 4 on January 12, 2026.

It is a new position: the filing shows no shares held directly before this purchase.

5 other insiders also bought at least $10,000 of AKTS within 30 days, which makes this a cluster buy.

In the 12 months up to this filing, Aktis Oncology, Inc. insiders reported 3 open-market purchases and 0 sales.

WallStPal Score: 62 out of 100, because of a brand-new position; a large purchase; 5 other insiders also bought.

What happened next: after 1 month the stock was up 0.3% (0.8 points better than the S&P 500); after 3 months the stock was down 0.9% (1.2 points better than the S&P 500); after 6 months the stock was up 42.1% (33.3 points better than the S&P 500). Based on weekly prices from the week of the purchase.

Our read

This one purchase is 57% of all insider buying at AKTS in the past year, the first open-market purchase by Ecor1 Capital, LLC in our records. It is worth reading next to the company's own results and news before drawing conclusions.

Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.

Examples

Big insider purchases have made news before. In January 2016, with bank stocks falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares, about $26 million of his own money, and the purchase was widely reported as a sign of confidence.

Explain it like I'm 13

Ecor1 Capital, LLC helps run Aktis Oncology, Inc.. Spending $40 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.

More: all AKTS insider trades · Ecor1 Capital, LLC's track record

Sources

  1. Form 4: Ecor1 Capital, LLC, purchase of AKTS · filed 2026-01-12
  2. Form 4: Helen Susan Kim, purchase · filed 2026-01-12
  3. Form 4: Vida Ventures II, LLC, purchase · filed 2026-01-12

The purchase filing and the other most recent Form 4 filings for the same company.

Report an error

Tell us what looks wrong on this page. We check every report against the original filing and fix mistakes on our corrections page.

Share this trade
XTelegram
My Desk · free

Sign in to follow

Follow stocks, members of Congress, famous investors and funds, and see what's new each time you come back.